Latest Options News

Charger Metals NL reports significant progress in its lithium exploration projects at Lake Johnston and Bynoe, backed by Rio Tinto's funding and a recent $0.77 million capital raise. Upcoming assay results and drilling programs could shape the company’s growth trajectory.

RLG Ltd has successfully raised $900,000 through a two-tranche placement to fund the development of its food and health products and expand global sales channels. The second tranche, involving options issuance, awaits shareholder approval.

Terra Uranium has significantly expanded its land holdings in the Athabasca Basin through strategic option agreements with ATHA Energy Corp, setting the stage for a robust 2025 drilling campaign amid a recovering uranium market.

Cyprium Metals has secured $13.5 million in a two-tranche placement and released a robust prefeasibility study for its Nifty Copper Complex, confirming strong economic viability with a pre-tax NPV of $1.12 billion. The company is also reviewing its Murchison assets and selling surplus equipment to streamline operations.

Aumake Limited reported a remarkable 239% increase in quarterly cash receipts, driven by a $16 million purchase order from Yangtze River and a strategic capital raise, positioning the company for robust growth in 2025.

Bellavista Resources has secured nearly A$5 million in capital to fund due diligence on advanced precious and base metal projects, while maintaining a strong cash position and progressing exploration at its Brumby Deposit.

FirstWave reports a stable Q2 FY25 with no cash burn for the second consecutive quarter, maintaining cash reserves at $1.68 million while securing key client contract renewals and launching a promising new product.

FirstWave Cloud Technology reports a cashflow positive first half of FY25, driven by strategic contract renewals and new technology launches, despite a slight decline in recurring revenue due to customer churn.

Argenica Therapeutics has dosed 80% of patients in its Phase 2 stroke trial and gained FDA orphan drug designations for its second candidate, ARG-006. The company reports a cash-positive quarter with $15 million in reserves.

Alterity Therapeutics has announced encouraging Phase 2 trial results for ATH434, showing significant slowing of disease progression in multiple system atrophy (MSA) patients and a strong safety profile. These findings mark a potential breakthrough in treating a disease with no approved therapies.

NEXION Group reported a robust 30% increase in cash receipts for Q2 FY25, driven by strong sales growth and new satellite sector contracts. The company is actively expanding its footprint in Southeast Asia while funding ongoing M&A activities through convertible notes.

Resource Mining Corporation reports promising copper-gold exploration results at its Mpanda project in Tanzania, secures $1 million in loan funding, and gains an option to acquire a 70% stake in a Saudi Arabia joint venture.